Department of Paediatric Subspecialties, Rheumatology and Immunology Service, KK Women's and Children's Hospital, Singapore, Singapore.
Department of Nursing, KK Women's and Children's Hospital, Singapore, Singapore.
Int J Rheum Dis. 2019 Jul;22(7):1271-1277. doi: 10.1111/1756-185X.13552. Epub 2019 Mar 21.
To describe the natural history and risk factors of renal involvement in our Henoch-Schönlein purpura (HSP) inception cohort.
HSP patients followed at our center for at least 6 months between 1/2009-4/2017 were included. A 2-year urinalysis (UA) monitoring protocol was adopted (6 monthly and another 6 of 3 monthly UA). Renal involvement included minimal renal involvement defined as isolated hematuria (urine red blood cells >5/high-power field or 10/µL) and/or proteinuria (urine protein >1+), and renal impairment defined as nephritic, nephrotic symptoms, or renal insufficiency. Recurrent HSP were excluded. Kaplan-Meier estimates and log-rank test were used to analyze the duration to onset and resolution of abnormal UA. Relationships between demographic and clinical features and renal involvement were studied using logistic regression analyses.
Two hundred and thirty-eight patients (52.9% male) were analyzed. Median duration of follow up was 20.6 (interquartile range 11.3-24.4) months. Eighty-nine children (37.4%) developed abnormal UA either at diagnosis (n = 43), or during follow up (n = 46), mostly (91.0%) within 6 months. Seventeen patients (7.1%) developed renal impairment. Among patients without renal impairment, an earlier subsidence (P = 0.008) was noted in those with normal UA at diagnosis and most abnormal UA resolved by 18 months in this subgroup. Older age at diagnosis was a risk factor of renal involvement (P < 0.001). Prednisolone therapy for non-renal indications did not affect the onset or duration of renal involvement.
Normal UA at diagnosis indicated a shorter duration of renal involvement. We propose a curtailed duration of follow up for those with normal and abnormal UA at diagnosis.
描述我们的过敏性紫癜(HSP)首发队列中肾脏受累的自然史和危险因素。
纳入 2009 年 1 月至 2017 年 4 月期间在我们中心至少随访 6 个月的 HSP 患者。采用 2 年的尿液分析(UA)监测方案(6 个月 6 次,3 个月 6 次 UA)。肾脏受累包括定义为孤立血尿(尿液红细胞>5/高倍视野或 10/µL)和/或蛋白尿(尿液蛋白>1+)的最小肾受累,以及定义为肾炎、肾病症状或肾功能不全的肾损害。排除复发性 HSP。采用 Kaplan-Meier 估计和对数秩检验分析异常 UA 的发病和缓解时间。使用逻辑回归分析研究人口统计学和临床特征与肾脏受累之间的关系。
共分析了 238 名患者(52.9%为男性)。中位随访时间为 20.6(四分位距 11.3-24.4)个月。89 名儿童(37.4%)在诊断时(n=43)或随访期间(n=46)出现异常 UA,大多数(91.0%)在 6 个月内。17 名患者(7.1%)出现肾损害。在无肾损害的患者中,诊断时 UA 正常者的缓解时间更早(P=0.008),且该亚组大多数异常 UA 在 18 个月内缓解。诊断时年龄较大是肾脏受累的危险因素(P<0.001)。非肾适应证的泼尼松治疗并未影响肾脏受累的发生或持续时间。
诊断时 UA 正常表明肾脏受累持续时间较短。我们建议对诊断时 UA 正常和异常的患者缩短随访时间。